BrainStorm Cell Therapeutics to move from Nasdaq to OTCQB after delisting; shares down

3 hours ago 1

BrainStorm Cell Therapeutics (NASDAQ:BCLI) received a Nasdaq delisting notice for non-compliance with equity requirements.
Trading on the Nasdaq Capital Market will be suspended on July 18, 2025.
Delisting is due to violation of Nasdaq's listing rule of minimum shareholder equity.

Recommended For You